This study focuses on treating a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It involves two medicines: V940, which is a personalized treatment that helps the immune system recognize and attack cancer, and pembrolizumab, which helps the immune system fight cancer cells. The study is split into two phases (Phase 2 and Phase 3) to test the safety and effectiveness of these treatments compared to the usual care, which might include surgery and radiation. The goal is to see if the combination of V940 and pembrolizumab helps patients live longer without their cancer coming back. Participants need to have a specific type of cSCC that can be surgically removed and meet other health criteria. They should not have other serious health conditions or treatments that may interfere with the study.

• The study involves multiple visits for treatment and check-ups.
• Participants will be monitored for side effects and treatment effectiveness.
• There might be risks and side effects from the treatments involved.